Literature DB >> 25455414

Reducing iodine load in hepatic CT for patients with chronic liver disease with a combination of low-tube-voltage and adaptive statistical iterative reconstruction.

Yoshifumi Noda1, Masayuki Kanematsu2, Satoshi Goshima1, Hiroshi Kondo1, Haruo Watanabe1, Hiroshi Kawada1, Nobuyuki Kawai1, Yukichi Tanahashi1, Toshiharu R T Miyoshi3, Kyongtae T Bae4.   

Abstract

PURPOSE: To prospectively assess the effect of reduced iodine load to contrast enhancement, image quality, and detectability of hepatocellular carcinomas (HCCs) in hepatic CT with a combination of 80 kVp tube voltage setting and adaptive statistical iterative reconstruction (ASIR) technique in patients with chronic liver disease.
MATERIALS AND METHODS: This HIPAA-compliant study was approved by our institutional review board and written informed consent was obtained in all patients. During a recent 9-month period, 170 consecutive patients (114 men and 56 women; age range, 40-85 years; mean, 67.7 years) with suspected chronic liver diseases were randomized into three CT groups according to the following iodine-load and tube-voltage protocols: 600 milligram per kilogram body weight (mg/kg) iodine load and 120 peak kilovolt (kVp) tube voltage setting (600-120 group), 500 mg/kg and 80 kVp (500-80 group), and 400mg/kg and 80 kVp (400-80 group). Analysis of variance was conducted to evaluate differences in CT number, background noise, signal-to-noise ratio (SNR), effective dose, HCC-to-liver contrast-to-noise ratio (CNR), and figure of merit (FOM). Sensitivity, specificity, and area under the receiver-operating-characteristic curve (AUC) were compared to assess the detectability of HCCs.
RESULTS: Vascular and hepatic enhancement in the 400-80 and 500-80 groups was comparable to or greater than that in the 600-120 group (P<.05). Subjective image quality was comparable among the three groups. Sensitivity, specificity, and AUC for detecting HCCs were comparable among the groups. The effective dose was kept low (3.3-4.1 mSv) in all three groups.
CONCLUSION: Iodine load can be reduced by 33% in CT of the liver with a combination of 80 kVp tube voltage setting and ASIR technique, without compromising the contrast enhancement, image quality, and detection of HCCs.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Adaptive statistical iterative reconstruction technique; Computed tomography; Contrast material; Liver; Low-tube-voltage

Mesh:

Substances:

Year:  2014        PMID: 25455414     DOI: 10.1016/j.ejrad.2014.10.008

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  9 in total

1.  Can virtual monochromatic images from dual-energy CT replace low-kVp images for abdominal contrast-enhanced CT in small- and medium-sized patients?

Authors:  Peijie Lv; Zhigang Zhou; Jie Liu; Yaru Chai; Huiping Zhao; Hua Guo; Daniele Marin; Jianbo Gao
Journal:  Eur Radiol       Date:  2018-11-30       Impact factor: 5.315

2.  Using 80 kVp on a 320-row scanner for hepatic multiphasic CT reduces the contrast dose by 50 % in patients at risk for contrast-induced nephropathy.

Authors:  Narumi Taguchi; Seitaro Oda; Daisuke Utsunomiya; Yoshinori Funama; Takeshi Nakaura; Masanori Imuta; Sadahiro Yamamura; Hideaki Yuki; Masafumi Kidoh; Kenichiro Hirata; Tomohiro Namimoto; Masahiro Hatemura; Noriyuki Kai; Yasuyuki Yamashita
Journal:  Eur Radiol       Date:  2016-05-30       Impact factor: 5.315

3.  Application of 80-kVp scan and raw data-based iterative reconstruction for reduced iodine load abdominal-pelvic CT in patients at risk of contrast-induced nephropathy referred for oncological assessment: effects on radiation dose, image quality and renal function.

Authors:  Yasunori Nagayama; Shota Tanoue; Akinori Tsuji; Joji Urata; Mitsuhiro Furusawa; Seitaro Oda; Takeshi Nakaura; Daisuke Utsunomiya; Eri Yoshida; Morikatsu Yoshida; Masafumi Kidoh; Machiko Tateishi; Yasuyuki Yamashita
Journal:  Br J Radiol       Date:  2018-03-02       Impact factor: 3.039

4.  Diagnostic performance and image quality of low-tube voltage and low-contrast medium dose protocol with hybrid iterative reconstruction for hepatic dynamic CT.

Authors:  Shintaro Ichikawa; Utaroh Motosugi; Tatsuya Shimizu; Marie Luise Kromrey; Yoshihito Aikawa; Daiki Tamada; Hiroshi Onishi
Journal:  Br J Radiol       Date:  2021-09-29       Impact factor: 3.039

5.  Optimized scan delay for late hepatic arterial or pancreatic parenchymal phase in dynamic contrast-enhanced computed tomography with bolus-tracking method.

Authors:  Yoshifumi Noda; Nobuyuki Kawai; Takuma Ishihara; Yoshiki Tsuboi; Tetsuro Kaga; Toshiharu Miyoshi; Fuminori Hyodo; Masayuki Matsuo
Journal:  Br J Radiol       Date:  2021-05-06       Impact factor: 3.629

6.  The combination of a reduction in contrast agent dose with low tube voltage and an adaptive statistical iterative reconstruction algorithm in CT enterography: Effects on image quality and radiation dose.

Authors:  Cui Feng; Di Zhu; Xianlun Zou; Anqin Li; Xuemei Hu; Zhen Li; Daoyu Hu
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

7.  Switching Monopolar Radiofrequency Ablation Using a Separable Cluster Electrode in Patients with Hepatocellular Carcinoma: A Prospective Study.

Authors:  Jin Woo Choi; Jeong Min Lee; Dong Ho Lee; Jeong-Hee Yoon; Kyung-Suk Suh; Jung-Hwan Yoon; Yoon Jun Kim; Jeong-Hoon Lee; Su Jong Yu; Joon Koo Han
Journal:  PLoS One       Date:  2016-08-30       Impact factor: 3.240

Review 8.  LI-RADS v2017 for liver nodules: how we read and report.

Authors:  Wolfgang Schima; Jay Heiken
Journal:  Cancer Imaging       Date:  2018-04-24       Impact factor: 3.909

9.  Reduction of the radiation dose and the amount of contrast material in hepatic dynamic CT using low tube voltage and adaptive iterative dose reduction 3-dimensional.

Authors:  Atsushi Nakamoto; Kiyohito Yamamoto; Makoto Sakane; Go Nakai; Akira Higashiyama; Hiroshi Juri; Shushi Yoshikawa; Yoshifumi Narumi
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.